Recurrent Adrenocortical Carcinoma Completed Phase 2 Trials for Oxaliplatin (DB00526)

IndicationStatusPhase
DBCOND0028855 (Recurrent Adrenocortical Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00091182Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous TreatmentTreatment